

Keratitis - Pipeline Review, H2 2020

<https://marketpublishers.com/r/KAA0067F282EN.html>

Date: October 2020

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: KAA0067F282EN

Abstracts

Keratitis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2020, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 2, 1, 1, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging

players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for

Keratitis (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Keratitis - Overview
- Keratitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Keratitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Keratitis - Companies Involved in Therapeutics Development
- Alfasigma SpA
- AmebaGone Inc
- Cumulus Pharmaceutical LLC
- Dobecure SL
- Editas Medicine Inc
- Eleusis Ltd
- EyeGate Pharmaceuticals Inc
- Fox Chase Chemical Diversity Center Inc
- iVeena Delivery Systems Inc
- MimeTech Srl
- NanoViricides Inc
- Oyster Point Pharma Inc
- RegeneRx Biopharmaceuticals Inc
- Riptide Bioscience Inc
- Shanghai Bendao Gene Technology Co Ltd
- Shenyang Sinqi Pharmaceutical Co Ltd
- Shulov Innovative Science Ltd
- Sinsa Labs Inc
- TGV-Inhalonix Inc
- Veloce BioPharma LLC

Viraze

Keratitis - Drug Profiles

acyclovir sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-2088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BD-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Bacterial Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELE-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethamsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IVMED-90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDE-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-55933 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIM-45 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-557 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

targocil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

timbetasin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udonitrectag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBP-245 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voriconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-9445 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Keratitis - Dormant Projects

Keratitis - Discontinued Products

Keratitis - Product Development Milestones

Featured News & Press Releases

May 14, 2020: ReGenTree announces efficacy results of the neurotrophic keratopathy phase 3 clinical trial with RGN-259

Apr 02, 2020: New provide pandemic response program to clients for T?4 in Corneal Wound Healing and Regeneration

Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 International Society for Research on Psychedelics

Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis

Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday

Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials

Sep 30, 2015: RegeneRx Receives \$500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259

Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Keratitis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Keratitis - Pipeline by Alfasigma SpA, H2 2020

Keratitis - Pipeline by AmebaGone Inc, H2 2020

Keratitis - Pipeline by Cumulus Pharmaceutical LLC, H2 2020

Keratitis - Pipeline by Dobecure SL, H2 2020

Keratitis - Pipeline by Editas Medicine Inc, H2 2020

Keratitis - Pipeline by Eleusis Ltd, H2 2020

Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2020

Keratitis - Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2020

Keratitis - Pipeline by iVeena Delivery Systems Inc, H2 2020

Keratitis - Pipeline by MimeTech Srl, H2 2020

Keratitis - Pipeline by NanoViricides Inc, H2 2020

Keratitis - Pipeline by Oyster Point Pharma Inc, H2 2020

Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2020

Keratitis - Pipeline by Riptide Bioscience Inc, H2 2020

Keratitis - Pipeline by Shanghai Bendao Gene Technology Co Ltd, H2 2020

Keratitis - Pipeline by Shenyang Sinqi Pharmaceutical Co Ltd, H2 2020

Keratitis - Pipeline by Shulov Innovative Science Ltd, H2 2020

Keratitis - Pipeline by Sinsa Labs Inc, H2 2020

Keratitis - Pipeline by TGV-Inhalonix Inc, H2 2020

Keratitis - Pipeline by Veloce BioPharma LLC, H2 2020

Keratitis - Pipeline by Viraze, H2 2020

Keratitis - Dormant Projects, H2 2020

Keratitis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Keratitis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Keratitis - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/KAA0067F282EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/KAA0067F282EN.html>